Assembly Biosciences (NASDAQ:ASMB) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) from a buy rating to a hold rating in a research note published on Monday.

Separately, HC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Monday.

Assembly Biosciences Stock Performance

Shares of ASMB stock traded down $0.03 on Monday, hitting $10.87. 1,947 shares of the stock traded hands, compared to its average volume of 24,866. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The firm's 50-day moving average price is $12.63 and its two-hundred day moving average price is $14.99. The stock has a market capitalization of $81.56 million, a PE ratio of -1.62 and a beta of 0.62.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $0.18. The business had revenue of $7.36 million during the quarter, compared to analysts' expectations of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. On average, equities research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Remove Ads

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton purchased 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ASMB. JPMorgan Chase & Co. grew its holdings in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 3,442 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at approximately $180,000. Marshall Wace LLP grew its stake in shares of Assembly Biosciences by 16.5% in the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 2,098 shares during the last quarter. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 3,635 shares during the last quarter. Finally, Man Group plc purchased a new position in Assembly Biosciences in the 4th quarter valued at $309,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.